SCHEDULE 13G: Avenue Capital Group Discloses 6.7% Passive Stake in CalciMedica, Inc.
Beneficial Ownership Report (Schedule 13G)
Avenue Venture Opportunities Fund II, L.P. and its affiliated entities, including Marc Lasry, have disclosed a 6.7% beneficial ownership stake in CalciMedica, Inc., primarily through convertible loans and warrants.
Summary
- Avenue Venture Opportunities Fund II, L.P., along with Avenue Capital Management II, L.P., Avenue Venture Opportunities Partners II, LLC, GL Venture Opportunities Partners II, LLC, and Marc Lasry, collectively reported beneficial ownership of 1,000,358 shares of CalciMedica, Inc. common stock.
- This aggregate amount represents 6.7% of CalciMedica, Inc.'s fully diluted common stock, based on 13,971,990 shares outstanding as of May 6, 2025.
- The beneficial ownership includes 359,195 shares of common stock issuable upon conversion of a $1 million loan to CalciMedica, Inc., convertible at the lender's option at a per share price of $2.784.
- Additionally, the ownership includes 641,163 shares of common stock issuable upon the exercise of outstanding warrants.
- Avenue Capital Management II, L.P. is identified as a registered investment adviser and the manager of Avenue Venture Opportunities Fund II, L.P., holding sole voting and dispositive power over the securities.
- The filing indicates a passive investment purpose, stating the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual, compliance-driven disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment stake by an institutional investor group in a publicly traded company, CalciMedica, Inc. It does not provide specific industry trends or competitive analysis but indicates an investment in the biotechnology or pharmaceutical sector, given CalciMedica's typical business.
Related Party Transactions
- The filing details a group of related entities (Avenue Venture Opportunities Fund II, L.P., Avenue Capital Management II, L.P., Avenue Venture Opportunities Partners II, LLC, GL Venture Opportunities Partners II, LLC, and Marc Lasry) acting in concert to report their collective beneficial ownership. Marc Lasry is identified as the ultimate beneficial owner of GL Venture Opportunities Partners II, LLC, which manages Avenue Venture Opportunities Partners II, LLC, the general partner of Avenue Venture Opportunities Fund II, L.P.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by an institutional investor group, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of event which requires the filing of this statement |
| 05/06/2025 | Date as of which the fully diluted shares of Common Stock of CalciMedica, Inc. were outstanding (13,971,990 shares) |
| 05/28/2025 | Date of filing of the Schedule 13G |
Keywords
CalciMedica Inc., Avenue Venture Opportunities Fund II L.P., SEC filing, Schedule 13G, beneficial ownership, common stock, convertible loan, warrants, passive investment, institutional investor, Marc Lasry
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.